



COPY OF PAPERS
ORIGINALLY FILED

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Mien-Chie Hung and Naoto Ueno

Serial No.: 09/943,984


Filed: August 31, 2001

For: SENSITIZATION OF HER-2/NEU
OVEREXPRESSING CANCER CELLS
TO CHEMOTHERAPY

Group Art Unit: 1632

Examiner: Unknown

Atty. Dkt. No.: UTSC:484USC1/TMB

CERTIFICATE OF MAILING 37 C.F.R 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
January 29, 2002	 Thomas M. Boyce
Date	Thomas M. Boyce

RESPONSE TO NOTICE TO FILE CORRECTED APPLICATION PAPERS DATED
DECEMBER 4, 2001

Commissioner for Patents
Washington, D.C. 20231

Sir:

The enclosed papers are in response to the Notice to File Corrected Application Papers ("the Notice") dated December 4, 2001, a copy of which is enclosed. No fees are believed due. However, should any fees be due in this application for any reason, the Assistant commissioner is authorized to deduct said fees from Fulbright & Jaworski Deposit Account No. 50-1212/10105728/MW01999.

A copy of the Notice is attached. Applicants respectfully request that the submitted papers be made of record in the present case.

Commissioner for Patents
January 29, 2002
Page 2

RESPONSE

Substitute Drawings

Applicants have herein provided substitute drawings in compliance with 37 C.F.R. §1.84.

Applicants state that no new matter is introduced in the substitute drawings.

Absences of "Sequence Listing" and "Sequence Listing in Computer Readable Format"

Applicants note that the Request for Filing Continuation Application Under 37 C.F.R. §1,53(b) inadvertently requested the transfer of the sequence listing from the parent application. This request was in error. Parent application Serial No. 08/809,021 filed March 19, 1997 does not include a sequence listing. Thus, no sequence listing is available for transfer in either paper or computer readable form and no transfer of the sequence listing is required in this continuation application.

Applicants regret the error. Applicants withdraw the request for transfer of sequence listing.

Conclusion

Applicants respectfully submit that these papers are fully responsive to the Notice. Any questions or inquiries regarding this application may be directed to the attorney listed below.

Commissioner for Patents
January 29, 2002
Page 3


Respectfully submitted,



Thomas M. Boyce
Reg. No. 43,508
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 536-3043 (voice)
(512) 536-4598 (fax)

Date: January 29, 2002



COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	RECEIVED/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/943,984	08/31/2001	Mien-Chie Hung	UTSC:484USC1/MBW

COPY OF PAPERS
ORIGINALLY FILED

CONFIRMATION NO. 2580
FORMALITIES LETTER



OC00000007153706

Mark B. Wilson
FULBRIGHT & JAWORSKI L.L.P.
Suite 2400
600 Congress Avenue
Austin, TX 78701

Date Mailed: 12/04/2001

NOTICE TO FILE CORRECTED APPLICATION PAPERS

Filing Date Granted

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

The required item(s) identified below must be timely submitted to avoid abandonment:

- Substitute drawings in compliance with 37 CFR 1.84 because:
 - drawing sheets do not have the appropriate margin(s) (see 37 CFR 1.84(g)). Each sheet must include a top margin of at least 2.5 cm. (1 inch), a left side margin of at least 2.5 cm. (1 inch), a right side margin of at least 1.5 cm. (5/8 inch), and a bottom margin of at least 1.0 cm. (3/8 inch);
- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c). Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A request to transfer the computer readable form from another application on file at the U.S. Patent and Trademark Office has been submitted as permitted by 37 C.F.R. 1.821(e). However, the request cannot be complied with since there is no compliant CRF present at the United States Patent and Trademark Office. Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

53C0

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP

600 CONGRESS AVENUE, SUITE 2400

AUSTIN, TEXAS 78701

TELEPHONE: 512/474-5201
FACSIMILE: 512/536-4598

WRITER'S INTERNET ADDRESS:
TBOYCE@FULBRIGHT.COM

WRITER'S DIRECT DIAL NUMBER:
512/536-3043



HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

COPY OF PAPERS
ORIGINALLY FILED

January 29, 2002

FILE: UTSC:484USC1
10105728

CERTIFICATE OF MAILING
37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

January 29, 2002

Date



Thomas M. Boyce

Commissioner for Patents
Washington, DC 20231

RE: *SN 09/943,984 "SENSITIZATION OF HER-2/NEU OVEREXPRESSING CANCER CELLS TO CHEMOTHERAPY" - Mien-Chie Hung and Naoto Ueno*
(Client Ref. MDA96-012)

Commissioner:


Enclosed for filing in the above-referenced patent application is:

- (1) A Response to Notice to File Corrected Application Papers Dated December 4, 2001;
- (2) A copy of Notice to File Corrected Application Papers;
- (3) 84 Drawings (FIG. 1A-36B) on 45 sheets; and
- (4) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/10105728/MBW.

Commissioner for Patents
January 29, 2002
Page 2

Respectfully submitted,



Thomas M. Boyce
Reg. No. 43,508

TB:SF
Encl.